Company profile
Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Rondecabtagene Autoleucel | phase3 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06153095 | phase1_2 | withdrawn | 2024-02-15 | 2025-01-09 | Lyell Immunopharma, Inc. | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
| NCT05274451 | phase1 | terminated | 2022-03-29 | 2024-11-27 | Lyell Immunopharma, Inc. | A Study to Investigate LYL797 in Adults With Solid Tumors |
| NCT05573035 | phase1 | terminated | 2022-12-19 | 2025-01-09 | Lyell Immunopharma, Inc. | A Study to Investigate LYL845 in Adults With Solid Tumors |
| NCT07188558 | phase3 | recruiting | 2026-01-12 | 2029-12-01 | Lyell Immunopharma, Inc. | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy |
| NCT05319314 | phase1_2 | recruiting | 2022-08-01 | 2028-06-01 | Lyell Immunopharma, Inc. | LYL273 for Patients With Relapsed or Refractory mCRC |
FDA applications (0)
No records yet.